Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37

Antimicrob Agents Chemother. 2015 Apr;59(4):2428-31. doi: 10.1128/AAC.04965-14. Epub 2015 Jan 20.

Abstract

Five cases of bacterial meningitis treated with ceftaroline (4 Streptococcus pneumoniae and 1 Staphylococcus aureus) are summarized here. The pharmacodynamics of human cathelicidin LL-37 and ceftaroline were evaluated against S. pneumoniae. Patients who received ceftaroline 600 mg every 8 h (q8h) (1 S. aureus and 3 S. pneumoniae) were successfully treated; treatment failed in 1 patient with S. pneumoniae who received 600 mg q12h. Ceftaroline increased the negative surface charge and sensitized S. pneumoniae to killing by LL-37, a peptide implicated in blood-brain barrier defense.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Antimicrobial Cationic Peptides / therapeutic use*
  • Cathelicidins
  • Ceftaroline
  • Cephalosporins / therapeutic use*
  • Cytochromes c / metabolism
  • Drug Interactions
  • Female
  • Humans
  • Male
  • Meningitis, Pneumococcal / drug therapy*
  • Microbial Sensitivity Tests
  • Middle Aged
  • Streptococcus pneumoniae / drug effects*
  • Survival Analysis

Substances

  • Anti-Bacterial Agents
  • Antimicrobial Cationic Peptides
  • Cephalosporins
  • Cytochromes c
  • Cathelicidins